Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Rova-T (rovalpituzumab tesirine)
i
Other names:
SC16LD6.5, antibody-drug conjugate SC16LD6.5, anti-SC16 ADC SC16LD6.5
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(5)
News
Trials
Company:
AbbVie
Drug class:
DNA replication inhibitor, DLL3-targeted antibody-drug conjugate
Related drugs:
‹
inotuzumab ozogamicin (28)
gemtuzumab ozogamicin (24)
idarubicin (22)
bendamustine (12)
loncastuximab tesirine-lpyl (7)
trastuzumab duocarmazine (6)
MEDI7247 (6)
ABBV-321 (6)
SGN-CD19B (5)
SOT102 (5)
MGC018 (5)
IMGN632 (4)
IMGN779 (3)
ADCT-301 (3)
BYON3521 (2)
CS5001 (2)
IKS03 (2)
ITC-6102RO (2)
NBE-002 (2)
SGN-CD123A (2)
SGN-CD352A (2)
TR1801-ADC (2)
ADCT-601 (2)
SGN-CD33A (2)
ADCT-211 (1)
ADCT-212 (1)
ADCT-701 (1)
DHES0815A (1)
MEDI3726 (1)
SGN-CD70A (1)
SC-003 (1)
ADCT-502 (0)
MDX-1203 (0)
MEDI2228 (0)
nimorazole (0)
PF-06647263 (0)
SC-006 (0)
SC-007 (0)
SYD1875 (0)
ADCT-602 (0)
inotuzumab ozogamicin (28)
gemtuzumab ozogamicin (24)
idarubicin (22)
bendamustine (12)
loncastuximab tesirine-lpyl (7)
trastuzumab duocarmazine (6)
MEDI7247 (6)
ABBV-321 (6)
SGN-CD19B (5)
SOT102 (5)
MGC018 (5)
IMGN632 (4)
IMGN779 (3)
ADCT-301 (3)
BYON3521 (2)
CS5001 (2)
IKS03 (2)
ITC-6102RO (2)
NBE-002 (2)
SGN-CD123A (2)
SGN-CD352A (2)
TR1801-ADC (2)
ADCT-601 (2)
SGN-CD33A (2)
ADCT-211 (1)
ADCT-212 (1)
ADCT-701 (1)
DHES0815A (1)
MEDI3726 (1)
SGN-CD70A (1)
SC-003 (1)
ADCT-502 (0)
MDX-1203 (0)
MEDI2228 (0)
nimorazole (0)
PF-06647263 (0)
SC-006 (0)
SC-007 (0)
SYD1875 (0)
ADCT-602 (0)
›
Associations
(5)
News
Trials
VERI cancer hierarchy
Reset Filters
DLL3 overexpression
Small Cell Lung Cancer
DLL3 overexpression
Small Cell Lung Cancer
rovalpituzumab tesirine
Sensitive: B - Late Trials
rovalpituzumab tesirine
Sensitive
:
B
rovalpituzumab tesirine
Sensitive: B - Late Trials
rovalpituzumab tesirine
Sensitive
:
B
DLL3 overexpression
Neuroendocrine Tumor
DLL3 overexpression
Neuroendocrine Tumor
rovalpituzumab tesirine
Sensitive: C3 – Early Trials
rovalpituzumab tesirine
Sensitive
:
C3
rovalpituzumab tesirine
Sensitive: C3 – Early Trials
rovalpituzumab tesirine
Sensitive
:
C3
DLL3 expression
Merkel Cell Carcinoma
DLL3 expression
Merkel Cell Carcinoma
rovalpituzumab tesirine
Sensitive: C4 – Case Studies
rovalpituzumab tesirine
Sensitive
:
C4
rovalpituzumab tesirine
Sensitive: C4 – Case Studies
rovalpituzumab tesirine
Sensitive
:
C4
DLL3 underexpression
Neuroblastoma
DLL3 underexpression
Neuroblastoma
rovalpituzumab tesirine
Sensitive: D – Preclinical
rovalpituzumab tesirine
Sensitive
:
D
rovalpituzumab tesirine
Sensitive: D – Preclinical
rovalpituzumab tesirine
Sensitive
:
D
DLL3 expression
Neuroblastoma
DLL3 expression
Neuroblastoma
rovalpituzumab tesirine
Sensitive: D – Preclinical
rovalpituzumab tesirine
Sensitive
:
D
rovalpituzumab tesirine
Sensitive: D – Preclinical
rovalpituzumab tesirine
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login